- Home
- GMAB vs AFG Comparison
GMAB vs AFG Comparison
Compare GMAB & AFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- AFG
- Stock Information
- Founded
- GMAB 1999
- AFG 1872
- Country
- GMAB Denmark
- AFG United States
- Employees
- GMAB N/A
- AFG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- AFG Property-Casualty Insurers
- Sector
- GMAB Health Care
- AFG Finance
- Exchange
- GMAB Nasdaq
- AFG Nasdaq
- Market Cap
- GMAB 12.1B
- AFG 11.4B
- IPO Year
- GMAB N/A
- AFG N/A
- Fundamental
- Price
- GMAB $22.34
- AFG $119.83
- Analyst Decision
- GMAB Buy
- AFG Hold
- Analyst Count
- GMAB 9
- AFG 5
- Target Price
- GMAB $40.71
- AFG $143.80
- AVG Volume (30 Days)
- GMAB 1.9M
- AFG 496.2K
- Earning Date
- GMAB 02-12-2025
- AFG 02-04-2025
- Dividend Yield
- GMAB N/A
- AFG 5.86%
- EPS Growth
- GMAB 83.82
- AFG 5.17
- EPS
- GMAB 16.85
- AFG 10.57
- Revenue
- GMAB $2,988,286,182.00
- AFG $7,986,000,000.00
- Revenue This Year
- GMAB $18.78
- AFG N/A
- Revenue Next Year
- GMAB $14.98
- AFG $5.73
- P/E Ratio
- GMAB $13.00
- AFG $11.33
- Revenue Growth
- GMAB 30.67
- AFG 7.17
- 52 Week Low
- GMAB $18.64
- AFG $118.97
- 52 Week High
- GMAB $31.88
- AFG $150.19
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- AFG 23.49
- Support Level
- GMAB $18.74
- AFG $125.19
- Resistance Level
- GMAB $22.55
- AFG $127.78
- Average True Range (ATR)
- GMAB 0.46
- AFG 2.62
- MACD
- GMAB 0.39
- AFG -0.92
- Stochastic Oscillator
- GMAB 94.64
- AFG 3.05
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About AFG American Financial Group Inc.
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. The company also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. The company's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.